Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Large group of people on a street

A team of mathematical modellers and epidemiologists at Oxford University’s Nuffield Department of Medicine release the latest model of a population responding to the coronavirus epidemic. The model - OpenABM-Covid19 - provides public health decision-makers with the ability to review the potential progression and outcome of the coronavirus, including fluctuations in infected individuals, hospitalisations, intensive care unit (ICU) admissions and deaths, and assess the impact of test and trace programmes.

OpenABM-Covid19 supports public health services, including the UK’s NHS England and NHS Wales, to forecast the epidemic and decide on the best balance and scale of epidemic control interventions over the coming months. Modelled interventions include digital contact tracing (exposure notification system), testing, ongoing physical distancing, self-isolation, mask wearing and further localised or national lockdown measures.

The full story is available on the Big Data Institute website

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.

RECOVERY Trial paper wins BMJ’s 2021 UK Research Paper of the Year Award

For the second year in a row, The British Medical Journal have selected a publication co-authored by Oxford University researchers for their prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare.